GSK Bio
NEWS
Ellume Limited is pleased to announce the appointment of Ms Joanne Moss to its Board as an Independent Non-Executive Director and Chair of Audit and Risk, effective immediately.
For BioSpace’s recent Ideal Employer report, life sciences professionals weighed in on the topic.
As the third quarter of 2019 comes to an end, most biopharma companies are reporting their earnings as they head into the final lap for the year. Here’s a look at some of the bigger companies’ reports that came out this week.
MorphoSys AG reported its financial results for the third quarter of 2019.
BioVersys AG announced, US$ 3.94 million in non-dilutive funding from CARB-X, with the possibility of US$ 4.98 million more if certain project milestones are met.
GlaxoSmithKline’s PARP inhibitor Zejula has been approved for wider use in some cancers.
Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, announces it has appointed Beverley Carr as Chief Business Officer, with effect from 4 November 2019.
A new method of synthesizing molecule arrangements in medicine could change the way many drugs, including the PARP inhibitor Zejula, a treatment for ovarian cancer, are produced.
The Dementia Discovery Fund this week welcomed more than 100 key stakeholders to its Annual Forum to discuss the opportunities and challenges surrounding the development of high-impact therapeutics for age-related dementias.
JOBS
IN THE PRESS